K G Nicholson

Summary

Country: UK

Publications

  1. ncbi request reprint Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza
    K G Nicholson
    Infectious Diseases Unit, Leicester Royal Infirmary, LE1 5WW, Leicester, UK
    Lancet 357:1937-43. 2001
  2. doi request reprint Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations
    Karl G Nicholson
    Infectious Diseases Unit, University Hospitals Leicester, Leicester, LE1 5WW, UK
    Vaccine 28:171-8. 2009
  3. ncbi request reprint Influenza
    Karl G Nicholson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester, UK
    Lancet 362:1733-45. 2003
  4. ncbi request reprint Influenza-related hospitalizations among young children in Leicestershire
    Karl G Nicholson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester University, Leicester, UK
    Pediatr Infect Dis J 22:S228-30. 2003
  5. doi request reprint Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine
    Tristan W Clark
    Infectious Diseases Unit, University Hospitals Leicester, and Department of Inflammation, Infection and Immunity, University of Leicester, Leicester, United Kingdom
    N Engl J Med 361:2424-35. 2009
  6. ncbi request reprint Influenza: vaccination and treatment
    I Stephenson
    Dept of Infection and Tropical Medicine, Leicester Royal Infirmary, UK
    Eur Respir J 17:1282-93. 2001
  7. ncbi request reprint Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    Lancet 362:1959-66. 2003
  8. ncbi request reprint Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, LE1 5WW, Leicester, UK
    Vaccine 21:1687-93. 2003
  9. pmc Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, United Kingdom
    J Virol 80:4962-70. 2006
  10. ncbi request reprint Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children
    Karl G Nicholson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    Vaccine 24:102-8. 2006

Collaborators

Detail Information

Publications18

  1. ncbi request reprint Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza
    K G Nicholson
    Infectious Diseases Unit, Leicester Royal Infirmary, LE1 5WW, Leicester, UK
    Lancet 357:1937-43. 2001
    ..We did an observer-blind, phase I, randomised trial in healthy volunteers to assess safety, tolerability, and antigenicity of MF59-adjuvanted and non-adjuvanted vaccines...
  2. doi request reprint Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations
    Karl G Nicholson
    Infectious Diseases Unit, University Hospitals Leicester, Leicester, LE1 5WW, UK
    Vaccine 28:171-8. 2009
    ..However, no vaccine formulation satisfied all European regulatory criteria for pandemic vaccines...
  3. ncbi request reprint Influenza
    Karl G Nicholson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester, UK
    Lancet 362:1733-45. 2003
    ....
  4. ncbi request reprint Influenza-related hospitalizations among young children in Leicestershire
    Karl G Nicholson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester University, Leicester, UK
    Pediatr Infect Dis J 22:S228-30. 2003
    ..We collected data on hospitalizations for influenza infections among young children in Leicester, UK...
  5. doi request reprint Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine
    Tristan W Clark
    Infectious Diseases Unit, University Hospitals Leicester, and Department of Inflammation, Infection and Immunity, University of Leicester, Leicester, United Kingdom
    N Engl J Med 361:2424-35. 2009
    ..The 2009 pandemic influenza A (H1N1) virus has emerged to cause the first pandemic of the 21st century. Development of effective vaccines is a public health priority...
  6. ncbi request reprint Influenza: vaccination and treatment
    I Stephenson
    Dept of Infection and Tropical Medicine, Leicester Royal Infirmary, UK
    Eur Respir J 17:1282-93. 2001
    ....
  7. ncbi request reprint Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    Lancet 362:1959-66. 2003
    ..In 1999, avian influenza A/Hong Kong/1073/99 (H9N2) virus emerged as a pandemic threat to human beings. We aimed to assess safety, tolerability, and antigenicity of whole virus and subunit H9N2 vaccines in healthy volunteers...
  8. ncbi request reprint Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, LE1 5WW, Leicester, UK
    Vaccine 21:1687-93. 2003
    ..001). MF59 significantly increased GMTs of antibody when compared to non-adjuvanted vaccine (P<0.001)...
  9. pmc Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, United Kingdom
    J Virol 80:4962-70. 2006
    ..The addition of the biovector to the vaccine given with 30 microg LTK63 enhanced mucosal IgA responses to A/Duck/Singapore (H5N3) (P=0.0491) and B/Guandong (P=0.0028) but not to A/Panama (H3N2). All vaccines were well tolerated...
  10. ncbi request reprint Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children
    Karl G Nicholson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    Vaccine 24:102-8. 2006
    ..Hospitalisation rates decreased markedly with referral age, so vaccine would need to be given in early infancy for maximum benefit...
  11. pmc Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials
    Nicola J Cooper
    Department of Epidemiology and Public Health, University of Leicester, Leicester LE1 6TP
    BMJ 326:1235. 2003
    ..To review the clinical effectiveness of oseltamivir and zanamivir for the treatment and prevention of influenza A and B...
  12. ncbi request reprint Confronting the avian influenza threat: vaccine development for a potential pandemic
    Iain Stephenson
    Influenza Branch, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Lancet Infect Dis 4:499-509. 2004
    ..Adjuvanted or whole-virus preparations may improve immunogenicity and allow sparing of antigen...
  13. ncbi request reprint Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy
    Iain Stephenson
    Influenza Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    J Infect Dis 191:1210-5. 2005
    ..0004), and 43% (P = .0128) in 14 subjects, respectively, compared with 27%, 27%, 0%, and 0% in 11 who received nonadjuvanted vaccine. These findings have implications for the rational design of pandemic vaccines against influenza H5...
  14. pmc Clinical description of a completed outbreak of SARS in Vietnam, February-May 2003
    Hoang Thu Vu
    Hanoi French Hospital, Hanoi, Vietnam
    Emerg Infect Dis 10:334-8. 2004
    ..Symptoms on admission were nonspecific, although fever, malaise, and lymphopenia were common. The complications of SARS included invasive intubation and ventilation (11.3%) and death (9.7%)...
  15. doi request reprint Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenza
    Allan J Wailoo
    Health Economics and Decision Science, ScHARR, University of Sheffield, Sheffield, UK
    Value Health 11:160-71. 2008
    ..To assess the cost-effectiveness of alternative strategies for the treatment of suspected influenza in otherwise healthy adults and to identify future research priorities using value of information analysis...
  16. doi request reprint Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1
    Iain Stephenson
    N Engl J Med 359:1631-3. 2008
  17. doi request reprint Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans
    Lance C Jennings
    Microbiology Department, Canterbury Health Laboratories, University of Otago, Christchurch, New Zealand
    Lancet Infect Dis 8:650-8. 2008
    ..WHO and governments should give urgent consideration to the use of these vaccines for the priming of individuals or communities who would be at greatest risk of infection if an H5N1 influenza pandemic were to emerge...
  18. pmc Sudden acute respiratory syndrome
    Maria Zambon
    BMJ 326:669-70. 2003